Objective-Inorganic polyphosphate (polyP) is known to modulate coagulation, inflammation, and metabolic pathways. It also amplifies inflammatory responses of HMGB1 (high mobility group box 1) in endothelial cells. The objective of this study was to evaluate the effect of polyP on von Willebrand factor (VWF) release from endothelial cells with or without HMGB1. Approach and Results-EA.hy926 endothelial cells were treated with different concentrations of polyP 70 alone or in combination with different concentrations of HMGB1. VWF release was measured by an ELISA assay in the absence or presence of pharmacological inhibitors of the receptor for advanced glycation end products, P2Y 1 , and Ca
P olyphosphates (polyP) are linear polymers of 3 to >1000 inorganic phosphate residues, which are linked together by ATP-like phosphoanhydride bonds. 1 It has been shown that polymers of medium size polyP containing ≈60 to 100 phosphate units are stored in dense granules of human platelets at high concentrations, which can be released into circulation on their activation by thrombin or other physiological stimuli during activation of the blood coagulation cascade. [2] [3] [4] Microorganisms under different environmental conditions may synthesize longer chain polyP containing >1000 phosphate units. 5, 6 Results of several recent studies have established an important role for polyP in the regulation of coagulation, inflammatory, and metabolic pathways. 3, 4, 7 In the clotting cascade, polyP functions as a procoagulant factor to promote thrombin generation via both, the intrinsic and extrinsic pathways of coagulation. 3, 4, 6 This function of polyP has been reported to be primarily mediated through the anionic polymer providing a template on which specific coagulation factors from both pathways assemble, thereby promoting coagulation reactions. 4, 6 In the proinflammatory pathway, we recently demonstrated that polyP can bind to the receptor for advanced glycation end products (RAGE) and P2Y 1 purinergic receptor on endothelial cells to mediate proinflammatory responses and phosphorylation-dependent inactivation of the upstream regulatory tuberous sclerosis complex, thereby leading to activation of the mTOR (mammalian target of rapamycin), Wnt/β-catenin, and nuclear factor-kB signaling pathways. [7] [8] [9] This endothelial cell activation results in the expression/ release of several presynthesized (and stored) and newly synthesized effector molecules, which are involved in modulating inflammatory and coagulation reactions. [10] [11] [12] [13] Among the stored effector molecules that are either readily mobilized to the cell surface or secreted out of the cell is von Willebrand factor (VWF), which is stored in Weibel-Palade bodies (WPB) and released on activation of endothelial cells by various physiological stimuli. [11] [12] [13] VWF plays a key role in regulating coagulation and inflammation under different pathophysiological conditions. The stimulatory effect of polyP on VWF release by endothelial cells has never been studied. In this study, we treated EA.hy926 endothelial cells with synthetic polyP, either similar to the size found in platelets (polyP 70 ) or found in bacteria (polyP 700 ), and measured the VWF release with an ELISA assay. We discovered that both sizes of polyP stimulate VWF secretion by EA.hy926 cells in a concentration-dependent manner. Boiled activated platelet releasates also induced VWF release by EA.hy926 cells, which was abolished if the releasates were pre-treated with either exopolyphosphatase or alkaline phosphatase. In addition to polyP, platelets are also a rich source of HMGB1 which, like polyP, is stored in dense granules; on activation of platelets, both molecules can be secreted into the circulation. 14, 15 Low concentrations of polyP or HMGB1 alone were inactive, but when combined, they functioned synergistically to induce VWF release by EA.hy926 cells. Interestingly, in a flow chamber assay using freshly isolated platelets, we discovered that the polyP 70 -HMGB1 complex effectively promoted VWF-platelet string formation that was inhibited by the anti-GPIbα (glycoprotein Ib alpha) antibody. The stimulatory effect of polyP 70 -HMGB1 was mediated through RAGE and P2Y 1 receptors because small interfering RNA silencing, soluble RAGE, and pharmacological inhibitors of the 2 receptors inhibited VWF release by EA.hy926 cells. Based on these results, we propose an as yet unrecognized function for polyP that links the procoagulant and inflammatory pathways by a novel mechanism through stimulation of VWF release by endothelial cells.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Reagents
Recombinant HMGB1 and Src inhibitor, PP2, were purchased from Sigma-Aldrich Chemical Co (St Louis, MO). RAGE antagonist peptide, the P2Y 1 inhibitor, MRS 2279, and cell the permeable Ca 2+ chelator BAPTA-AM (1,2-bis[2-aminophenoxy]ethane-N,N,N',N'-tetraacetic acid tetrakis[acetoxymethyl ester]) were purchased from Tocris Bioscience (Minneapolis, MN). Phospholipase C (PLC) inhibitor U73122, RAGE, and P2Y 1 antibodies were from Santa Cruz Biotechnology Inc (Santa Cruz, CA). Antibodies against phospho-Src, phospho-PLC were from Cell Signaling Technology (Beverly, MA). PolyP 70 was a generous gift from Dr James Morrissey (University of Michigan, Ann Arbor, MI). Platelet releasates were gifts from Dr Stephanie Smith (University of Michigan, Ann Arbor, MI) and prepared as described. 6 PolyP 700 was purchased from Kerafast (Boston, MA). Anti-VWF polyclonal antibody (A0082) was purchased from DAKO (Carpinteria, CA). Biotin-labeled anti-VWF monoclonal antibody was obtained from Cederlane Laboratories (Burlington, NC). Standard VWF protein was from Abcam (Cambridge, MA). GPIbα blocking mouse monoclonal antibody (clone-AK2) was purchased from BioRad (Hercules, CA). Anti-HMGB1 neutralizing monoclonal antibody (clone-3E8) was from Biolegend (San Diego, CA). Anti-factor VIII monoclonal antibody (clone-R8B12) from Green Mountain Antibodies (Burlington, VT). Recombinant human factor VIII (FVIII) was a gift from Bayer (Berkeley, CA). Alkaline phosphatase was obtained from New England Biolabs Inc (Beverly, MA) and EcPPXc, the recombinant polyP-binding domain of Escherichia coli exopolyphosphatase fused to maltose-binding protein and a His6 tag, was prepared as described. 16 The extracellular domain of RAGE (soluble RAGE) was expressed in Escherichia coli using SUMO expression/purification plasmid system with a His tag and purified using a combination of Ni-Sepharose and Hi-Trap Q HP column chromatography, as described. 
Cell Culture Experiments
Primary human umbilical vein endothelial cells (HUVECs, Invitrogen) and transformed HUVECs (EA.hy926 cells, ATCC) were maintained as described.
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VWF Measurement by Sandwich ELISA
EA.hy926 cells were treated with polyP, HMGB1, or with their combination for the indicated period of time, and VWF release was measured using a Sandwich ELISA assay. Briefly, high binding 96-well plates (Greiner bio one, Monroe, NC) were coated with anti-VWF polyclonal antibody (1 µg/mL) in bicarbonate coating buffer (pH, 9.6) overnight at 4°C. After blocking for 1 hour at room temperature with 1% BSA, plates were incubated with the diluted endothelial cell culture supernatants for 2 hours. After washing with TBST (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl containing 0.05% tween 20), the plates were incubated with biotin-labeled anti-VWF monoclonal antibody (1 µg/mL) for another 2 hours. Plates were washed again with TBST and incubated with horse radish peroxidase-conjugated streptavidin for 30 minutes. After washing, 3,3′,5,5′-tetramethylbenzidine substrate solution was added, the reaction stopped with 2 N sulfuric acid, and absorbance measured at 450 nm using a plate reader. A reference standard curve of VWF was generated using standard VWF, and the amount of VWF secretion in the conditioned media was calculated.
Western Blotting
Treated endothelial cells were lysed in cell lysis buffer (50 mmol/L Tris-HCL, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% NP40, 1 mmol/L PMSF (phenylmethane sulfonyl fluoride), 1× protease inhibitor cocktail). Proteins were resolved by (8%-10%) SDS-PAGE and then transferred to polyvinylidene fluoride membranes. After blocking with 1% BSA in TBST, membranes were incubated with the primary antibody against phospho-PLCγ and phospho-Src (1:1000) for overnight at 4°C. After washing with PBST (phosphate-buffered saline, 0.1% Tween 20), membranes were incubated in horse radish peroxidase-conjugated secondary antibodies (1:5000), and specific immune-reactive bands were identified using an Enhanced Chemiluminescence detection system.
VWF-Platelet String Formation
Blood was collected from healthy adult volunteers (following approved institutional review board protocol) in acid-citrate dextrose and platelet-rich plasma prepared by centrifuging the blood at 150g for 15 minutes. The platelet-rich plasma was again centrifuged at 900g for 5 minutes to collect platelets. Platelets were resuspended at 10 million/mL in HEPES-Tyrodes buffer (134 mmol/L NaCl, 12 mmol/L NaHCO 3 , 2.9 mmol/L KCl, 0.34 mmol/L NaH 2 PO 4 , 5 mmol/L HEPES, 5 mmol/L glucose) containing 1 mmol/L EDTA and 1% human serum albumin. EA.hy926 cells were exposed to different treatments in tissue culture dishes, and the isolated platelets perfused over them in a parallel-plate flow chamber at a shear rate of 8 Five to 10 random fields were selected for recording platelet string formation. Platelet strings were defined as ≥3 platelets aligning in the direction of the flow. Platelet string lengths were determined as the distance between the first and the last platelet in a single continuous string stretched in the direction of the flow as described.
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FVIII-VWF Binding Assay
FVIII-VWF binding assay were conducted as described previously. 19 Briefly, high binding 96 well plates were coated with anti-VWF polyclonal antibody (1 µg/mL) in bicarbonate coating buffer (pH, 9.6) overnight at 4°C. Plates were blocked for 1 hour with 1% BSA in TBST at room temperature. After washing, plates were incubated with cell culture supernatant for 2 hours followed by incubation with recombinant human FVIII (200 ng/mL) for 2 hours. Immobilized VWF-bound FVIII was detected by incubation with anti-FVIII mouse monoclonal antibody (2 µg/mL, clone-R8B12) and horse radish peroxidase-conjugated anti-mouse antibody (1:5000) as described. 20 After washing, 3,3′,5,5′-tetramethylbenzidine substrate solution was added and reaction stopped with 2 N sulfuric acid, and absorbance was measured at 450 nm. A reference standard curve of VWF-FVIII binding was generated using serial dilutions of standard VWF.
Immunofluorescence Microscopy
Confluent EA.hy926 cells were either treated with polyP 70 and HMGB1 or left untreated for 16 hours. Cells were then washed with PBS and fixed with 4% paraformaldehyde for 10 minutes. After blocking with 1% BSA in PBS for 1 hour at room temperature, cells were incubated with anti-VWF rabbit polyclonal antibody (10 µg/ mL) overnight. After washing with PBS, cells were incubated with Alexa Flour-488-labeled goat anti-rabbit IgG as the secondary antibody (1:300). The 4′,6-diamidino-2-phenylindole, hydrochloride was used as nuclear stain. Images were acquired with Nikon C2 confocal microscope.
Statistical Analysis
Data were expressed as mean±SD (unless otherwise specified) from ≥3 independent experiments. Data were analyzed by the Student t test, and group data were analyzed using ANOVA followed by Bonferroni post hoc test using Graph Pad Prism7 (Graph Pad Prism, CA). A P<0.05 was considered statistically significant.
Results
PolyP and HMGB1 Induce VWF Release by Endothelial Cells
PolyP 70 (polyP concentration is expressed in terms of phosphate monomer) induced VWF secretion by transformed HUVECs (EA.hy926 endothelial cells) in a concentration-dependent ( Figure 1A ) and time-dependent manner ( Figure 1B ). The minimum concentration of polyP 70 required to induce a significant amount of VWF secretion is 25 µmol/L ( Figure 1A ). The VWF concentration in the supernatant increased significantly within 1 hour of incubation and reached its maximum level after 8 hours of polyP treatment ( Figure 1B ). Extracellular HMGB1 is known to induce platelet aggregation and endothelial cell activation. Thus, we explored the effect of HMGB1 on VWF release from EA.hy926 cells. Similar to results described above for polyP 70 , HMGB1 induced VWF release from EA.hy926 cells in a concentration-( Figure 1C ) and timedependent manner ( Figure 1D ). The HMGB1-induced VWF release started with late kinetics of 3 hours of stimulation and reached its maximum level after 16 hours of treatment with 40 nmol/L HMGB1 ( Figure 1D ). We previously demonstrated that polyP 70 could bind HMGB1 with high affinity to augment the proinflammatory effect of the nuclear protein. 8 To determine whether polyP 70 can amplify the HMGB1-mediated VWF release, cells were treated with subthreshold concentrations of HMGB1 together with a low concentration of polyP 70 (2.5 µmol/L) which by itself exhibits no VWF releasing function. Analysis of the concentration dependence of the HMGB1 effect indicated that 2.5 µmol/L polyP 70 was sufficient to significantly amplify the effect of a low concentration of HMGB1 (5 nmol/L, inactive by itself) on VWF release from endothelial cells ( Figure 1E ). Similar results were obtained if the concentration of HMGB1 (5 nmol/L) was kept constant in the presence of increasing concentrations (2.5-10 nmol/L) of polyP 70 ( Figure 1F ). The released VWF in the cell culture supernatant was functional as evidenced by its ability to interact with the purified human FVIII in the FVIII-VWF binding assay ( Figure 1G ). To determine whether any endogenous HMGB1, possibly secreted into the cell culture supernatant during the experiments, contributes to VWF release, the ability of polyP 70 to induce VWF release was evaluated in the absence and presence of a HMGB1 neutralizing antibody. The results indicated that a significant amount of endogenous HMGB1 is not secreted into the supernatant to influence the assay ( Figure I in the online-only Data Supplement). This is evidenced by the similar extent of VWF release by polyP 70 in either the absence or presence of the HMGB1 neutralizing antibody ( Figure IB in the online-only Data Supplement).
To explore the possible mechanism through which polyP 70 and HMGB1 induced VWF release from EA.hy926 cells, the effect of both polyP 70 and HMGB1, alone or in combination, on the secretion of Ang-2 (angiopoietin-2), which is localized with VWF in WPB granules of endothelial cells, 21 was evaluated. Results showed that, similar to VWF release, low concentrations of both stimuli, which were individually inactive in the assay, but in combination dramatically induced Ang-2 release by EA.hy926 cells ( Figure 1H ). These results strongly suggest that the polyP 70 -HMGB1 complex induces VWF release through exocytosis of the WPB storage granules in endothelial cells. The efficiency of polyP 70 -HMGB1 (2.5 μmol/L polyP and 5 nmol/L HMGB1 as in Figure 1F ) to induce VWF release from primary HUVECs was essentially identical to that observed in transformed HUVECs (EA.hy926 cells; Figure II in the online-only Data Supplement). Thus, because of ease of manipulation, all of the studies of the article were conducted using EA.hy926 cells.
HMGB1 and PolyP 70 Induced VWFDependent Platelet String Formation
To delineate the functional consequences of polyP 70 -and HMGB1-mediated VWF secretion by EA.hy926 cells, the capacity of the treated cells to recruit platelets to their surfaces was analyzed in a flow chamber-based assay system. Thus, freshly isolated human platelets were perfused over EA.hy926 cells, treated with polyP 70 , HMGB1, or with their combination, at the laminar shear rate of 8 dynes/cm 2 as described.
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The results showed that cells treated with either polyP 70 or HMGB1 alone did not significantly recruit platelets; however, the combination of the 2 stimuli effectively induced the recruitment of the platelets as evidenced by the platelet string formation on the surface of the cells (Figure 2A-2D) . The synergistic polyP 70 -HMGB1-mediated platelet string formation was inhibited by the anti-GPIbα antibody ( Figure 2C ). Treatment with polyP 70 alone did not cause any observable platelet string formation; however, HMGB1 by itself mediated a small amount of shorter length VWF strings (<10 µm) on cells. However, the combination of polyP 70 and HMGB1 lead to formation of much longer length VWF-platelet strings (≈80-100 µm; Figure 2D ). In a separate experiment, immunofluorescent staining of VWF on EA.hy926 cells indicated that a fraction of VWF in polyP 70 -HMGB1-treated cells is not secreted into the supernatant but remains on the surface of endothelial cells ( Figure 2E ).
Boiled Platelet Releasate Induces VWF Release
Activated platelets are known to secrete soluble polyP polymers of ≈60 to 100 phosphate units long into circulation. 2, 4, 22 To demonstrate that the platelet-derived polyP can similarly induce VWF release, we treated EA.hy926 cells with the platelet releasates obtained from thrombin receptor agonist peptide-activated platelets as described. 6, 7 To ensure that only the effect of polyP is measured in the assay, platelet releasates were boiled for 30 minutes, which deactivates all other activators that may be present in the platelet releasates except polyP. 6 Results showed that boiled platelet releasates induced VWF release in a concentration-dependent manner ( Figure 3A) . Thus, a platelet releasate ratio of 0.04 to 0.08 (platelet releasate volume/total volume) effectively induced VWF release by EA.hy926 cells, and the stimulatory effect was not inhibited by boiling ( Figure 3A ), but it was abolished by the specific polyP inhibitor, EcPPXc, or alkaline phosphatase which cleaves polyP ( Figure 3B) . Similarly, platelet releasate-derived polyP was capable of amplifying the VWF releasing effect of a low concentration of HMGB1. Thus, a platelet releasate ratio of 0.02, which does not have any effect on VWF release by itself, significantly promoted VWF release in the presence of a low concentration of HMGB1 (5 nmol/L, inactive by itself), and the stimulatory effect was abolished by prior treatment of the platelet releasates with either EcPPXc or alkaline phosphatase ( Figure 3C ), suggesting that the effect is specifically mediated through the platelet polyP.
PolyP 700 Is More Effective in Inducing VWF Release
Previous results have indicated that longer chain polyP polymers have higher procoagulant and proinflammatory activity. 6, 8 In agreement with those results, we found that polyP 700 is more efficient in inducing VWF release from EA.hy926 cells. Thus, in contrast to 25 µmol/L polyP 70 , which was required to induce a significant amount of VWF release ( Figure 1A) , a polyP 700 concentration of 2.5 µmol/L (≈10-fold lower) was sufficient to induce the same amount of VWF release ( Figure 4A) . Similarly, the amplification effect of polyP 700 on HMGB1 required a much lower concentration (250 nmol/L) of the polymer to induce VWF release by endothelial cells ( Figure 4B ). Platelets were perfused on different treatment groups with or without pre-incubation with the GP1bα monoclonal antibody. A total of 5 to 10 random fields were selected for recording platelet string formation. Average number of platelet strings per field were determined as ≥3 platelets aligned in the direction of the flow. A, Untreated control. B, Fluorescent image of 5-chloromethylfluorescein diacetate-labeled platelet string formation on polyP 70 -HMGB1-treated cells. C, Average number of strings per field was counted in different treatment groups. D, Average length of platelet strings was measured in different treatment groups and expressed as mean±SEM. **P<0.01, ***P<0.005. E, Evaluation of the cell surface-associated VWF by immunocytochemistry. VWF on cell surface was detected using specific anti-VWF rabbit antibody followed by secondary staining with Alexa Flour-488-conjugated anti-rabbit IgG as described in Materials and Methods. Scale bar, 10 µm. Statistical significance was analyzed by 1-way ANOVA followed by Bonferroni post hoc test (C and D).
PolyP-HMGB1-Mediated VWF Release Is Dependent on RAGE and P2Y 1 Receptor Signaling
Previous results have indicated that the synergistic signaling effect of polyP and HMGB1 in inducing a proinflammatory phenotype in endothelial cells is mediated through 2 receptors, RAGE and P2Y 1 . 8 The small interfering RNA silencing of either RAGE ( Figure 5A ) or P2Y 1 ( Figure 5B ) significantly reduced the polyP 70 -HMGB1-mediated secretion of VWF from EA.hy926 cells. These results suggest that a similar signaling mechanism accounts for the synergistic effect of polyP 70 and HMGB1 in inducing VWF release from endothelial cells. In agreement with these results, MRS2279 as an inhibitor of P2Y 1 signaling ( Figure 5C ) and soluble RAGE as a competitive inhibitor of RAGE signaling ( Figure 5D ), both significantly inhibited the VWF releasing function of polyP 70 -HMGB1 in EA.hy926 cells.
PolyP and HMGB1 Induce VWF Release Through PLC and Src Phosphorylation
Immunoblotting studies presented in Figure 6A demonstrate that the polyP 70 -HMGB1 complex increases the phosphorylation of both Src and PLC in EA.hy926 cells. RAGE signaling was involved in the activation of both signaling molecules because a RAGE antagonist peptide ( Figure 6B 
Discussion
We recently demonstrated that polyP 70 binds chromatin-associated nuclear proteins, HMGB1, and histone 4 to amplify their proinflammatory signaling functions in both cellular and animal models. 8 We discovered that the synergistic effect of polyP in promoting the proinflammatory effect of the nuclear proteins is mediated through polyP interacting with 2 cell surface receptors, RAGE and P2Y 1 on endothelial cells. 8 In this study, for the first time, we have discovered that polyP by a similar mechanism promotes HMGB1-mediated VWF release from endothelial cells. This hypothesis is supported by the observation that small interfering RNA silencing of either RAGE or P2Y 1 significantly reduced polyP 70 -HMGB1-mediated VWF release from endothelial cells. Further support for this hypothesis was provided by the results from 2 competitive inhibitors of RAGE and a chemical inhibitor of P2Y 1 (MRS2279), all of which significantly decreased the polyP 70 -HMGB1-mediated secretion of VWF. Both polyP and HMGB1 were also individually capable of inducing VWF release, nevertheless, their combination exhibited a synergistic effect, thereby dramatically reducing the concentration of each stimulus required to induce VWF release. The RAGE-and P2Y 1 -dependent VWF releasing function of polyP 70 -HMGB1 required phosphorylation of Src, PLC, and Ca 2+ signaling because the inhibitors of these signaling molecules all significantly reduced VWF release from endothelial cells. It is worth noting that in an in vivo mouse model, it has been demonstrated that HMGB1 facilitates hypoxia-mediated VWF upregulation through TLR2 (Toll-like receptor-2) signaling. 23 This is consistent with previous findings that, in addition to signaling via TLR4 and RAGE, 8, 24 HMGB1 can also signal through TLR2; however, the combination of polyP and HMGB1 has been found to signal primarily through the RAGE receptor. 8 Endothelial cells store VWF multimers primarily in the WPB storage granules, which are released by exocytosis when cells are stimulated with thrombin, histamine, terminal complement components, epinephrine, and a variety of other calcium-mediated agonists. [11] [12] [13] Agonist-mediated release of VWF is composed of high molecular weight VWF multimers that on release from endothelial cells can recruit platelets and form long string-like structures that play critical roles in regulating primary hemostasis at vascular injury sites. [11] [12] [13] The results of the flow chamber assay with freshly isolated human platelets, perfused over polyP 70 -HMGB1-treated EA.hy926 endothelial cells, suggest that a combination of the 2 stimuli effectively induced the recruitment of the platelets to cell surfaces as evidenced by platelet string formation on the surface of endothelial cells ( Figure 2B ). The synergistic polyP 70 -HMGB1-mediated platelet string formation was mediated through the interaction of the GPIbα receptor present on platelets with the endothelial cell surface VWF because it was effectively abolished by prior incubation of platelets with an anti-GPIbα antibody ( Figure 2C  and 2D) . Analysis of the length of VWF-platelet strings on EA.hy926 cells indicated that polyP 70 alone did not cause any observable platelet string formation, and HMGB1 mediated only a small number of shorter length VWF strings (<10 µm). By contrast, the combination of polyP 70 and HMGB1 led to formation of a significant amount of longer VWF-platelet strings (≈80-100 µm; Figure 2D ). The stimulated secretion of VWF has been hypothesized to result from exocytosis of larger size VWF multimers stored in WPB storage granules although shorter size VWF multimers may be released continuously through a constitutive process that does not require stimulation. [11] [12] [13] The circulating plasma type of VWF that functions as a carrier protein for FVIII may constitute this latter form of the protein. Analysis of both the time course of VWF release by polyP 70 ( Figure 1B ) and the size of the VWF-platelet strings indicates that polyP 70 -HMGB1 induced a regulated exocytosis of WPB storage granules. Further support for this hypothesis was provided by the observation that the combination of polyP 70 and HMGB1 also released Ang-2, which is known to be colocalized with VWF in WPB storage granules. These observations further suggest that the ELISA assay used to measure the VWF release may underestimate the amount of polyP-mediated VWF release from endothelial cells because it only detects VWF secreted to the cell culture supernatant but not the VWF species that remain on the surface of endothelial cells. Immunofluorescence staining of VWF in polyP 70 -HMGB1-treated cells by confocal microscopy ( Figure 2E ) further supports our hypothesis that a fraction of VWF remains associated with endothelial cells.
Previous results have indicated that polyP modulates procoagulant, fibrinolytic, and complement pathways through providing an ionic surface on which different protease-activation complexes assemble. This function of polyP has been demonstrated to be of high physiological importance for the activation of the contact pathway in which factors XII, XI, and prekallikrein are activated to initiate the intrinsic pathway of the coagulation cascade. 3, 4, 6, 15 It was recently demonstrated that polyP could also bind VWF through a similar mechanism to enhance its interaction with platelet GPIbα, thereby promoting the binding of platelets to VWF and as such contributing to hemostasis. 25 Interestingly, this previous study evaluated the platelet polyP levels of a cohort of type 1 von Willebrand disease and noted that the platelet polyP levels of these individuals are ≈40% lower than the controls, leading the authors to hypothesize that there is a relationship between platelet polyP levels and VWF activity, which may be of high physiological relevance. 25 In the context of these previous findings, we envision a possible hemostatic role for the platelet polyPmediated VWF release (by itself or in combination with basal HMGB1) through this mechanism, which may be compromised in individuals with type 1 von Willebrand disease, who reportedly have lower platelet polyP levels. 25 This hypothesis warrants further investigation; however, if true, it would support a therapeutic role for polyP in type 1 von Willebrand disease. It is of interest to note that the capacity of polyP to amplify the HMGB1-mediated release of VWF from endothelial cells can also promote thrombosis by recruiting platelets under certain pathological conditions. Moreover, by amplifying HMGB1 (or histone H4) signaling through presenting the nuclear protein to its receptor, RAGE, polyP can contribute to the pathogenesis of various acute and chronic proinflammatory disorders, including severe sepsis, diabetes mellitus, atherosclerosis, and cancer. [26] [27] [28] In support of this, RAGE null mice (or wild-type mice treated with soluble RAGE) and inhibitors of HMGB1 have been shown to improve survival in various animal models of acute inflammation and severe sepsis in response to endotoxin challenge. [29] [30] [31] [32] Elevated levels of VWF and HMGB1 have been found to be associated with disease severity and clinical outcome in infectious diseases. 27, 33 Based on our results, we propose the following model for polyP-HMGB1-mediated VWF release and platelet string formation (Figure 7 ). We hypothesize that the interaction of the polyP-loaded HMGB1 with RAGE and P2Y 1 receptors results in the activation of several proinflammatory signaling molecules, including phosphorylation of Src and PLC, thereby leading to an elevation of intracellular Ca 2+ levels, which facilitates the fusion of WPB storage granules with the endothelial cell membrane and the exocytosis of the stored VWF and other molecules. A fraction of VWF, which is released into the cell culture supernatant, is detected by ELISA, but a fraction of the released VWF (possibly larger molecular weight species) remains bound to the cell surface to recruit platelets and form platelet strings. The polyPmediated VWF release or RAGE signaling occurs much more efficiently with longer chain polyP 700 that may be released during bacterial infection, thus the VWF-platelet string formation is expected to occur with a much higher efficiency with low nmol/L concentrations of longer chain polyPs. 8 In this context, complement-mediated bacterial lysis can result in the release of such longer chain polyP molecules that can bind HMGB1 (or histones), thereby dramatically amplifying thrombotic and proinflammatory responses by RAGE signaling in general and by VWF-platelet string formation in particular as demonstrated in this study. Thus, in addition to its potential therapeutic utility in different types of bleeding disorders, polyP may also constitute an ideal target for developing inhibitors capable of neutralizing the function of polyP in thrombotic and inflammatory disorders. 70 -HMGB1 (high mobility group box 1). The interaction of the highly negatively charged polyP 70 with the positively charged residues of HMGB1 eliminates their repulsive interactions with the similarly positively charged residues of the ligand-binding N-terminal domain of receptor for advanced glycation end products (RAGE), thereby promoting the interaction of HMGB1 with RAGE via the acidic domain of the ligand. PolyP binds to multiple HMGB1 molecules and presents them to multiple receptors, thereby inducing receptor dimerization (oligomerization) and activation by facilitating the cooperative interaction of the cytoplasmic tails of the receptor with the adaptor molecule mDia1, which is responsible for initiating downstream signaling. Because polyP can also bind P2Y 1 , the interaction between RAGE and HMGB1-loaded polyP is further enhanced by a bridging mechanism. This dual receptor interaction mechanism results in the activation of several proinflammatory signaling molecules (ie, activation of PI3K/Akt, Erk, p38, JNK, nuclear factor-kB, ROS generation; not shown), including phosphorylation of Src and PLC, thereby leading to an elevation of intracellular Ca 2+ levels, which facilitates the fusion of Weibel-Palade bodies (WPB) storage granules with the endothelial cell membrane and the exocytosis of the stored VWF. A fraction of VWF is released into the cell culture supernatant, which is detected by ELISA, but a fraction of the high molecular weight VWF polymers remains bound to the cell surfaces, which recruits platelets and forms platelet strings (see the text for more details). Akt indicates protein kinase B; Erk, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; and ROS, reactive oxygen species.
